AVANIA
16.3.2023 14:01:40 CET | Business Wire | Press release
Avania, a leading, global medical technology contract research organization (CRO), today announced its appointment of Todd M. Pope as the new chairman of the board of directors. Todd brings 30 years of technology, medical device, and leadership experience across large cap and startup MedTech and was named to TIME Magazine’s 2018 list of 50 Most Influential People in Healthcare. Having spent the last 20 years in CEO roles in both private and public companies, he also currently serves as the chairman of the board of directors of AdvaMed ACCEL, the division within AdvaMed dedicated to addressing the unique needs of small and startup medical technology manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005199/en/
Avania Names Todd M. Pope New Chairman of the Board (Photo: Business Wire)
“I am very pleased to take on this role at such a dynamic time and support Avania on its growth journey,” said Pope. “After a rewarding career leading companies in the MedTech industry, I am motivated by the opportunity to work alongside the senior management team to execute on Avania’s transformational business strategy.”
Todd’s previous roles included global president of Johnson & Johnson Cordis, president and CEO of TransEnterix, as well as other senior executive positions within the MedTech space. Todd is currently director of the boards of Distalmotion and Humacyte, and a partner at Revival Healthcare Capital.
“Todd’s long history of leadership, coupled with his deep operating and commercial experience in the MedTech space makes him an ideal person for this role,” said Sapna Hornyak, president and CEO of Avania. “I look forward to working closely with Todd to ensure Avania continues to make a positive impact for all stakeholders, including Avania’s customers, our people, and the MedTech community. The senior management team along with the board of directors are excited about the future and look forward to bringing Avania to the next new phase with our new chairman.”
“We are very excited to be working with Todd,” added Edouard Pillot, managing partner, and Enrico Grasso, partner of Astorg Mid-Cap, which has majority interest in Avania. “He brings a wealth of MedTech industry experience and relationships that will provide invaluable connections with customers as well as insights into their evolving needs, and how Avania can best serve them. Todd’s leadership experience, with small and large businesses, will also support Avania as it grows and scales.”
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005199/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 10:00:00 CEST | Press release
Including Executives and Policymakers from the UK Government, NVIDIA, AWS, Tony Blair Institute, AstraZeneca and Virgin Atlantic The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead
MOVIVA® launch spotlight at ESGE Days 20267.5.2026 09:58:00 CEST | Press release
“Turn down the food noise” During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.”
Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 09:57:00 CEST | Press release
GBCI Europe Impact Report 2026 highlights that 53% of European real estate leaders prioritize resilience as a financial imperative. Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of t
Criteo Selects Navan to Modernize Global Travel Management7.5.2026 09:00:00 CEST | Press release
Global commerce intelligence platform delivers high employee satisfaction with Navan Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Gli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom